Select Bibliography

Filter by any of these (after searching):

N0874

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 6 items

Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902.

Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary - Primary - Neuro-Onc - N0874 , ABTC-0902

Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology

Cerhan, Jane H , Anderson, S Keith , Butts, Alissa M , Porter, Alyx B ... - - Neurooncol Pract - 2019

Manuscript - Secondary-not-in-original - Primary - Health Outcome - N0577 , A221101 , N0874 , N107C

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma

Ellingson, Benjamin M , Abrey, Lauren E , Nelson, Sarah J ... - - Neuro-oncology - 2018

Manuscript - Secondary-not-in-original - Primary - Neuro-Onc - N0874

Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial

Galanis, E. , Sarkaria, J. , Anderson, K. , Wu, W. , Jaeckle, K. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary - Primary - Neuro-Onc - N0874

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

Galanis, Evanthia , Anderson, S Keith , Miller, C Ryan ... - - Neuro-oncology - 2018

Manuscript - Primary - Primary - Neuro-Onc - N0874

Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)

Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary - Primary - Neuro-Onc - N0874